<DOC>
	<DOCNO>NCT01291459</DOCNO>
	<brief_summary>Background Rationale Raltegravir Maraviroc , first class 2 new family antiretroviral drug demonstrate high potency treatment experience naive patient . Both drug appear well tolerate low metabolic toxicity . No data currently available concern combination 2 drug . Hypothesis Maraviroc + Raltegravir potent enough maintain virological efficacy naive patient infected CCR5 HIV-1 previously treat 6 month Maraviroc-Raltegravir-Tenofovir-Emtricitabine combination .</brief_summary>
	<brief_title>Pilot Study Maraviroc/Raltegravir Naive HIV-1 Patients</brief_title>
	<detailed_description>Objectives : - To establish ability Maraviroc-Raltegravir combination maintain HIV-1 viral load &lt; 50 copies/ml week 48 naive patient infected CCR5 HIV-1 , follow initial 6 month phase Maraviroc-Raltegravir-Tenofovir-Emtricitabine combination ( Intent treat strategy analysis ) - To study CD4 progression baseline week 48 - To study time virological failure simplification phase study ( week 24 week 48 ) - To study proportion patient HIV RNA &lt; 50 copies/ml time point - To study kinetics viral load decrease baseline week 12 - To study kinetics proviral DNA decrease baseline week 12 , 24 , 36 48 - To study clinical biological tolerance Maraviroc-Raltegravir combination week 48 Study Design/ Clinical Plan Pilot , multicenter , national , uncontrolled study</detailed_description>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age ≥ 18 year old runin visit HIV1 infection Antiretroviral treatmentnaive CD4 ≥ 200 /mm3 HIV RNA ≥ 1000 copies/ml HIVRNA ≤ 100,000 copies/ml Antiretroviral therapy indicate accord current guideline CCR5tropic virus accord Trofile ES® assayGeno2Pheno algorithm use predefined false positive rate 20 % No significant NRTI , NNRTI PI resistance mutation Freelygiven , write , informed consent obtain ; patient investigator sign consent form ( late day runin visit perform examination require trial ) Patient cover French national health insurance scheme Women childbearing potential use effective contraception ( barrier method ) Pregnant breastfeed woman Patients age 18 year Patients deprive liberty judicial administrative , hospitalized patient without consent , patient admit health social purpose research Persons major subject measure legal protection unable consent Previous antiretroviral therapy ( exception postexposure prophylaxis HIV serology negative &gt; 3 month last dose antiretroviral drug ) CXCR4tropic virus , dual/mixedtropic virus undetermined tropism screen Presence significant NRTI , NNRTI PI resistance mutation ( ) Infection coinfection HIV2 , group O N HIV1 Acute phase opportunistic infection Undergoing treatment tuberculosis Undergoing chemotherapy and/or radiotherapy neoplastic disease Decompensated cirrhosis ( ChildPugh class B C ) HIVHBV coinfection . Patients HIVHCV coinfection permit participate absence decompensated cirrhosis ( ChildPugh class B C ) , hepatocytolysis &gt; 3 time upper limit normal treatment HCV ensue 12 month indicate . PAtients occult HBV exclude . ( positive AcHBc , negative AcHBs , negative AgHBs , positive HBV DNA ) Coadministration prohibit treatment ( see SPCs product ) Laboratory parameter : Haemoglobin &lt; 7g/dl , neutrophil count &lt; 500/mm3 , platelet count &lt; 50,000/mm3 , creatinine clearance &lt; 50 ml/min , alkaline phosphatase , AST , ALT bilirubin ≥ 3 time upper limit normal Patient refuse participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>naive patient</keyword>
	<keyword>maraviroc</keyword>
	<keyword>raltegravir</keyword>
</DOC>